The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Morpholino Antisense Oligomers: Design, Preparation, and Properties
Abstract
Antisense promised major advances in treating a broad range of intractable diseases, but in recent years progress has been stymied by technical problems, most notably inadequate specificity, ineffective delivery into the proper subcellular compartment, and unpredictable activity within cells. Herein is an overview of the design, preparation, and properties of Morpholino oligos, a novel antisense structural type that solves the sequence specificity problem and provides high and predictable activity in cells. Morpholino oligos also exhibit little or no nonantisense activity, afford good water solubility, are immune to nucleases, and are designed to have low production costs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zamecnik, P. C., & Stephenson, M. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.280 · Cited by 1,792
Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?
Stein, C. A., & Cheng, Y.-C. (1993) · Science · doi:10.1126/science.8351515 · Cited by 1,303
Peptide nucleic acids (PNA). Oligonucleotide analogs with an achiral peptide backbone
Egholm, M., Buchardt, O., Nielsen, P. E., & Berg, R. H. (1992) · Journal of the American Chemical Society · doi:10.1021/ja00031a062 · Cited by 738
Role of RNase H in hybrid-arrested translation by antisense oligonucleotides.
Walder, R. Y., & Walder, J. A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5011 · Cited by 450
Antisense Gene Inhibition by Oligonucleotides Containing C-5 Propyne Pyrimidines
Wagner, R. W., Matteucci, M. D., Lewis, J. G., Gutierrez, A. J., Moulds, C., & Froehler, B. C. (1993) · Science · doi:10.1126/science.7684856 · Cited by 405
Resistance of Morpholino Phosphorodiamidate Oligomers to Enzymatic Degradation
HUDZIAK, R. M., BAROFSKY, E., BAROFSKY, D. F., WELLER, D. L., HUANG, S.-B., & WELLER, D. D. (1996) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1996.6.267 · Cited by 275
Self-citationHoke, G. D., Draper, K., Freier, S. M., Gonzalez, C., Driver, V. B., Zounes, M. C., & Ecker, D. J. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.20.5743 · Cited by 248
Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides
Cazenave, C., Stein, C. A., Loreau, N., Thuong, N. T., Neckers, L. M., Subasinghe, C., Hélène, C., Cohen, J. S., & Toulmé, J.-J. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.11.4255 · Cited by 238
Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression
(1992) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(08)60574-7 · Cited by 233
Morpholino and Phosphorothioate Antisense Oligomers Compared in Cell-Free and In-Cell Systems
SUMMERTON, J., STEIN, D., HUANG, S. B., MATTHEWS, P., WELLER, D., & PARTRIDGE, M. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.63 · Cited by 179
Self-citation
Cited by
Effective targeted gene ‘knockdown’ in zebrafish
Nasevicius, A., & Ekker, S. C. (2000) · Nature Genetics · doi:10.1038/79951 · Cited by 2,483
Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches
Beermann, J., Piccoli, M.-T., Viereck, J., & Thum, T. (2016) · Physiological Reviews · doi:10.1152/physrev.00041.2015 · Cited by 1,726
Therapeutic siRNA: state of the art
Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X.-J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0207-x · Cited by 1,586
Zebrafish as a Model Vertebrate for Investigating Chemical Toxicity
Hill, A. J., Teraoka, H., Heideman, W., & Peterson, R. E. (2005) · Toxicological Sciences · doi:10.1093/toxsci/kfi110 · Cited by 1,374
Overcoming cellular barriers for RNA therapeutics
Dowdy, S. F. (2017) · Nature Biotechnology · doi:10.1038/nbt.3802 · Cited by 1,139
Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin
Boyden, E. D., & Dietrich, W. F. (2006) · Nature Genetics · doi:10.1038/ng1724 · Cited by 860
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 828
Kok, F. O., Shin, M., Ni, C.-W., Gupta, A., Grosse, A. S., van Impel, A., Kirchmaier, B. C., Peterson-Maduro, J., Kourkoulis, G., Male, I., et al. (2015) · Developmental Cell · doi:10.1016/j.devcel.2014.11.018 · Cited by 755
Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts
Stewart, M. P., Langer, R., & Jensen, K. F. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00678 · Cited by 747
Morpholino antisense oligomers: the case for an RNase H-independent structural type
Summerton, J. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00150-5 · Cited by 664
Self-citationDesigning Chemically Modified Oligonucleotides for Targeted Gene Silencing
Deleavey, G. F., & Damha, M. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.07.011 · Cited by 589
Inhibition of microRNA function by antimiR oligonucleotides
Stenvang, J., Petri, A., Lindow, M., Obad, S., & Kauppinen, S. (2012) · Silence · doi:10.1186/1758-907x-3-1 · Cited by 560
Lon protease preferentially degrades oxidized mitochondrial aconitase by an ATP-stimulated mechanism
Bota, D. A., & Davies, K. J. A. (2002) · Nature Cell Biology · doi:10.1038/ncb836 · Cited by 557
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Dhuri, K., Bechtold, C., Quijano, E., Pham, H., Gupta, A., Vikram, A., & Bahal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062004 · Cited by 545
Nucleic-acid therapeutics: basic principles and recent applications
Opalinska, J. B., & Gewirtz, A. M. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd837 · Cited by 537
Morpholino Oligos: Making Sense of Antisense?
Heasman, J. (2002) · Developmental Biology · doi:10.1006/dbio.2001.0565 · Cited by 533
βCatenin Signaling Activity Dissected in the Early Xenopus Embryo: A Novel Antisense Approach
Heasman, J., Kofron, M., & Wylie, C. (2000) · Developmental Biology · doi:10.1006/dbio.2000.9720 · Cited by 523
Eteplirsen in the treatment of Duchenne muscular dystrophy
Lim, K. R., Maruyama, R., & Yokota, T. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s97635 · Cited by 495
Alter, J., Lou, F., Rabinowitz, A., Yin, H., Rosenfeld, J., Wilton, S. D., Partridge, T. A., & Lu, Q. L. (2006) · Nature Medicine · doi:10.1038/nm1345 · Cited by 494
A Primer for Morpholino Use in Zebrafish
Bill, B. R., Petzold, A. M., Clark, K. J., Schimmenti, L. A., & Ekker, S. C. (2009) · Zebrafish · doi:10.1089/zeb.2008.0555 · Cited by 474
Silencing disease genes in the laboratory and the clinic
Watts, J. K., & Corey, D. R. (2012) · The Journal of Pathology · doi:10.1002/path.2993 · Cited by 470
Real-time PCR detection chemistry
Navarro, E., Serrano-Heras, G., Castaño, M. J., & Solera, J. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.10.017 · Cited by 457
Chemical modification and design of anti-miRNA oligonucleotides
Lennox, K. A., & Behlke, M. A. (2011) · Gene Therapy · doi:10.1038/gt.2011.100 · Cited by 433
The Medicinal Chemistry of Therapeutic Oligonucleotides
Wan, W. B., & Seth, P. P. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00551 · Cited by 429
Optochemical Control of Biological Processes in Cells and Animals
Ankenbruck, N., Courtney, T., Naro, Y., & Deiters, A. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201700171 · Cited by 419
Progress in antisense technology
Crooke, S. T. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104408 · Cited by 417
Efficacy of systemic morpholino exon‐skipping in duchenne dystrophy dogs
Yokota, T., Lu, Q., Partridge, T., Kobayashi, M., Nakamura, A., Takeda, S., & Hoffman, E. (2009) · Annals of Neurology · doi:10.1002/ana.21627 · Cited by 398
Delivery of oligonucleotide‐based therapeutics: challenges and opportunities
Hammond, S. M., Aartsma‐Rus, A., Alves, S., Borgos, S. E., Buijsen, R. A. M., Collin, R. W. J., Covello, G., Denti, M. A., Desviat, L. R., Echevarría, L., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013243 · Cited by 388
siRNA-based approaches in cancer therapy
Devi, G. R. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700931 · Cited by 353
Therapeutic Oligonucleotides: State of the Art
Smith, C. I. E., & Zain, R. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021050 · Cited by 323
Drugs in development for toxoplasmosis: advances, challenges, and current status
Alday, H., & Doggett, J. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s60973 · Cited by 321
Connexin‐specific cell‐to‐cell transfer of short interfering RNA by gap junctions
Valiunas, V., Polosina, Y. Y., Miller, H., Potapova, I. A., Valiuniene, L., Doronin, S., Mathias, R. T., Robinson, R. B., Rosen, M. R., Cohen, I. S., et al. (2005) · The Journal of Physiology · doi:10.1113/jphysiol.2005.090985 · Cited by 297
The transcription factor Sox9 is required for cranial neural crest development in Xenopus
Spokony, R. F., Aoki, Y., Saint-Germain, N., Magner-Fink, E., & Saint-Jeannet, J.-P. (2002) · Development · doi:10.1242/dev.129.2.421 · Cited by 295
Antisense oligonucleotides in therapy for neurodegenerative disorders
Evers, M. M., Toonen, L. J. A., & van Roon-Mom, W. M. C. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.03.008 · Cited by 286
Positional cloning of heart and soul reveals multiple roles for PKCλ in zebrafish organogenesis
Horne-Badovinac, S., Lin, D., Waldron, S., Schwarz, M., Mbamalu, G., Pawson, T., Jan, Y.-N., Stainier, D. Y. R., & Abdelilah-Seyfried, S. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00458-4 · Cited by 283
The Zebrafish as a Model Organism to Study Development of the Immune System
TRAVER, D., HERBOMEL, P., PATTON, E. E., MURPHEY, R. D., YODER, J. A., LITMAN, G. W., CATIC, A., AMEMIYA, C. T., ZON, L. I., & TREDE, N. S. (2003) · Advances in Immunology · doi:10.1016/s0065-2776(03)81007-6 · Cited by 276
Anti-miRNA oligonucleotides: A comprehensive guide for design
Lima, J. F., Cerqueira, L., Figueiredo, C., Oliveira, C., & Azevedo, N. F. (2018) · RNA Biology · doi:10.1080/15476286.2018.1445959 · Cited by 276
Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications
Aartsma-Rus, A., & van Ommen, G.-J. B. (2007) · RNA · doi:10.1261/rna.653607 · Cited by 267
Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders
Shahryari, A., Saghaeian Jazi, M., Mohammadi, S., Razavi Nikoo, H., Nazari, Z., Hosseini, E. S., Burtscher, I., Mowla, S. J., & Lickert, H. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00868 · Cited by 262
Berdougo, E., Coleman, H., Lee, D. H., Stainier, D. Y. R., & Yelon, D. (2003) · Development · doi:10.1242/dev.00838 · Cited by 261
Naip5 Affects Host Susceptibility to the Intracellular Pathogen Legionella pneumophila
Wright, E. K., Goodart, S. A., Growney, J. D., Hadinoto, V., Endrizzi, M. G., Long, E. M., Sadigh, K., Abney, A. L., Bernstein-Hanley, I., & Dietrich, W. F. (2003) · Current Biology · doi:10.1016/s0960-9822(02)01359-3 · Cited by 260
Suls, A., Jaehn, J. A., Kecskés, A., Weber, Y., Weckhuysen, S., Craiu, D. C., Siekierska, A., Djémié, T., Afrikanova, T., Gormley, P., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.09.017 · Cited by 219
Engelhart, A. E., & Hud, N. V. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a002196 · Cited by 101
Poulain, M., & Lepage, T. (2002) · Development · doi:10.1242/dev.129.21.4901 · Cited by 96
From “Cellular” RNA to “Smart” RNA: Multiple Roles of RNA in Genome Stability and Beyond
Michelini, F., Jalihal, A. P., Francia, S., Meers, C., Neeb, Z. T., Rossiello, F., Gioia, U., Aguado, J., Jones-Weinert, C., Luke, B., et al. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00487 · Cited by 85
Fully automated fast-flow synthesis of antisense phosphorodiamidate morpholino oligomers
Li, C., Callahan, A. J., Simon, M. D., Totaro, K. A., Mijalis, A. J., Phadke, K.-S., Zhang, G., Hartrampf, N., Schissel, C. K., Zhou, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24598-4 · Cited by 57
Identification of GSK-3 as a potential therapeutic entry point for epilepsy.
Aourz, N., Serruys, A.-S. K., Chabwine, J. N., Balegamire, P. B., Afrikanova, T., Edrada-Ebel, R., Grey, A. I., Kamuhabwa, A. R., Walrave, L., Esguerra, C. V., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00281 · Cited by 49
Sekhon, H. S., London, C. A., Sekhon, M., Iversen, P. L., & Devi, G. R. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2007.10.028 · Cited by 45
Metadata
- Authors
- SUMMERTON, J., & WELLER, D.
- Venue
- Antisense and Nucleic Acid Drug Development
- Publisher
- SAGE Publications
- Published
- 1997-06
- Volume
- 7
- Issue
- 3
- Pages
- 187-195
- ISSN
- 1087-2906 (ISSN-L)
- OpenAlex
- W2071230707
- Cited by
- 1,116
- References
- 20
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.